
|Articles|July 31, 2006
Fourth indication approved for gemcitabine
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Half of Patients Have Used Online Pharmacies But Under 10% Identified Safe Sites
2
Potential Complexities in Billing for Vaccine Services Under Medicare
3
Older Adults Lack Understanding of OTC Drugs Despite Common Use
4
COVID-19 Infection During First Trimester Increases Risk of Neonatal Risks
5












































































































































